Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241665 | 0.90 | MAPT (0.56) | MEN1TSHRKMT2AHDAC1MAPT | |
| SCHEMBL19555085 | 0.89 | MAPK8 (0.66) | HDAC1MAPTMAPK8MAPK9SLC9A1 | |
| SCHEMBL17241596 | 0.88 | TSHR (0.62) | MEN1TSHRKMT2AHDAC1MAPT | |
| SCHEMBL24004722 | 0.86 | TSHR (0.76) | MEN1TSHRKMT2AHDAC1MAPT | |
| SCHEMBL6466889 | 0.85 | P2RX4 (0.64) | MEN1KMT2AHDAC1MAPT | |
| SCHEMBL3556560 | 0.83 | HDAC1 (0.67) | HDAC1MAPK8MAPK9TP53THRB | |
| SCHEMBL6510739 | 0.82 | KMT2A (0.72) | MEN1KMT2AHDAC1MAPTMAPK8 | |
| SCHEMBL10084710 | 0.82 | MEN1 (0.52) | MEN1KMT2AMAPTTP53THRB | |
| SCHEMBL6396627 | 0.81 | PARG (0.47) | HDAC1MAPTMAPK8MAPK9THRB | |
| SCHEMBL1058355 | 0.80 | HDAC1 (0.66) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | MEN1 1184/4885TSHR 1662/4885KMT2A 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.